,51,52 This finding suggests a potential synthetic lethality approach, wherein targeting both CDK12/13 and the PI3K/AKT signaling pathway could yield substantial therapeutic benefits for prostate cancer. This evidence concerns the gene AKT1 and prostate carcinoma.